Selecting an agent for prophylaxis of venous thromboembolism.
Myers
John
J
Department of Pharmacy, Baptist Hospital of East Tennessee, Knoxville, TN 37920, USA. jmyers@bhset.org
D000925:Anticoagulants; D003362:Cost-Benefit Analysis; D017985:Dalteparin / Q000191:economics / Q000627:therapeutic use*; D017984:Enoxaparin / Q000191:economics / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D005572:Formularies, Hospital as Topic; D006495:Heparin, Low-Molecular-Weight / Q000191:economics / Q000627:therapeutic use*; D006761:Hospitals; D006801:Humans; D010607:Pharmacy Service, Hospital; D011183:Postoperative Complications / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000517:prevention & control; D013810:Therapeutic Equivalency; D013923:Thromboembolism / Q000517:prevention & control*; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin; D017985:Dalteparin